We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » With FDA Nod, Novartis to Explore Zolgensma in Older SMA Patients
With FDA Nod, Novartis to Explore Zolgensma in Older SMA Patients
After a satisfactory review of toxicology data, the FDA has given Novartis the green light to test its spinal muscular atrophy (SMA) gene therapy, Zolgensma (AVXS-101), in patients aged two to 18 years.